Vaccini - Generalità

JAMA, 24 marzo 2022 | “Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes”
JAMA, 24 marzo 2022 | “Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes”
JAMA, editoriale 24 marzo 2022 | “COVID-19 mRNA Vaccines During PregnancyNew Evidence to Help Address Vaccine Hesitancy”
MMWR, 4 marzo 2022 | “Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022”
BMJ, 2 marzo 2022 |“Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis”
New England Journal of Medicine, 2 marzo 2022 | “Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant”

JAMA, 7 febbraio 2022 | “Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection”
The Lancet, 4 febbraio 2022 | “Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden”
ECDC , 31 gennaio 2022 | “Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA”
New England Journal of Medicine, 27 gennaio 2022 | “Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines”
The Lancet infectious Diseases, 27 gennaio 2022 | “Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy”
ECDC , 31 gennaio 2022 | “Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA”
New England Journal of Medicine, 27 gennaio 2022 | “Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines”
The Lancet infectious Diseases, 27 gennaio 2022 | “Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy”
New England Journal of Medicine, 26 gennaio 2022 | “Homologous and Heterologous Covid-19 Booster Vaccinations”
JAMA, 21 gennaio 2022 | “Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants”
JAMA, 21 gennaio editoriale | “Booster Vaccination to Prevent COVID-19 in the Era of Omicron An Effective Part of a Layered Public Health Approach”
ECDC, 20 gennaio 2022 | “Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update”
New England Journal of Medicine , 12 gennaio 2022 | “Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines”
Nature, 12 gennaio 2022 | “COVID vaccines safely protect pregnant people: the data are in”
New England Journal of Medicine , 5 gennaio 2022 | “Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants”
Nature, 14 dicembre 2021 | “Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection”
The Lancet, 2 dicembre 2021 | “Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial”
New England Journal of Medicine , 1 dicembre 2021 | “Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans”
JAMA, 24 novembre 2021 | “COVID-19 Vaccine Makers Plan for Annual Boosters, but It’s Not Clear They’ll BeNeeded”
New England Journal of Medicine, editoriale 1 dicembre 2021 | “Covid-19 mRNA Vaccines — Six of One, Half a Dozen of the Other”
New England Journal of Medicine , 11 novembre 2021 | “The Future of SARS-CoV-2 Vaccination — Lessons from Influenza”
The Lancet, 11 novembre 2021 | “Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial”
JAMA, 5 novembre 2021 | “Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years”
JAMA, 4 novembre 2021 | “Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity”
New England Journal of Medicine , 1 dicembre 2021 |“Covid-19 Vaccine Effectiveness in New York State”
JAMA, editoriale 4 novembre 2021 | “Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity”
The Lancet infectious Diseases , 29 ottobre 2021 | “Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study”
The Lancet infectious Diseases , editoriale 29 ottobre 2021| “What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?”
MMWR, 29 ottobre 2021 | “The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021”
New England Journal of Medicine, 15 ottobre 2021 | “Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines”
Nature, 14 ottobre 2021 | “China’s COVID vaccines have been crucial — now immunity is waning”
The Lancet Respiratory Medicine, 29 settembre 2021 | “COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study”
MMWR, 24 settembre 2021 | “Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021”
New England Journal of Medicine, 22 settembre 2021 | “Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase”
New England Journal of Medicine, 22 settembre 2021 | “Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel”
New England Journal of Medicine, 15 settembre 2021 | “Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel”
New England Journal of Medicine , 8 settembre 2021 | “Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings”
JAMA, 3 settembre 2021 | “Surveillance for Adverse Events After COVID-19 mRNA Vaccination”
New England Journal of Medicine , editoriale 8 settembre 2021 |“Covid-19 Vaccine Effectiveness and the Test-Negative Design”
JAMA, editoriale 3 settembre 2021 | “Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink”
JAMA, 3 settembre 2021 | “Surveillance for Adverse Events After COVID-19 mRNA Vaccination”
New England Journal of Medicine , editoriale 8 settembre 2021 |“Covid-19 Vaccine Effectiveness and the Test-Negative Design”
JAMA, editoriale 3 settembre 2021 | “Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink”
MMWR, 18 agosto 2021 | “Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021”
MMWR, 18 agosto 2021 | “Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021”
MMWR, 30 luglio 2021 | “COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021”